Trade Mark Journal No.2021/053 31 December 2021
WO0000001630674 (5)
Office of origin: United States of America
Date of International Registration:18 October 2021
Date of designation in the UK:
18 October 2021

The mark consists of three curved vertical lines consisting of dots of graduated sizes, with the word "NUGALVIQ" to the right of the design.
International priority date claimed: 13 October 2021
(United States of America)
(97072078)
- Class 5
- Pharmaceutical preparations for treatment of rare orphan diseases; pharmaceutical preparations for treatment of diseases that impact sugar and glucose metabolism; pharmaceutical preparations for inhibiting aldose reductase; pharmaceutical preparations for treatment of galactosemia, sorbitol dehydrogenase (SORD) deficiency and PMM2-congenital disorder of glycosylation (PMM2-CDG).
Applied Therapeutics, Inc.
Representative: Anna Kurian Shaw Hogan Lovells US LLP, 555 13th Street NW, Washington DC 20004, UNITED STATES OF AMERICA